Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Surprise! There’s a tumour in which Keytruda doesn’t work
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Roche and Celgene set for battle in acute myelogenous leukaemia
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
Immunogen fails to leap Forward
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
